# China NMPA Product Recall - Angiography Imaging System

Source: https://www.globalkeysolutions.net/records/china_product_recall/ge-medical-systems-scs/176ca2c7-2ee1-41e3-aaa8-219d56f800b3/
Source feed: China

> China NMPA product recall for Angiography Imaging System by GE Medical Systems SCS published April 28, 2014. Recall level: . The National Medical Products Administration (NMPA) published a notice on April 28, 2014, detailing 

---

## Details

- Record Type: CHINA_PRODUCT_RECALL
- Title: GE Medical Systems SCS of France has recalled its angiography imaging system.
- Company Name: GE Medical Systems SCS
- Publication Date: 2014-04-28
- Product Name: Angiography Imaging System
- Recall Reason: Innova systems equipped with CE-certified PDBs (distribution boxes) may fail to start properly after power is applied or after a system reset. Furthermore, they may unexpectedly shut down during inspections, potentially resulting in the complete loss of real-time interventional imaging.
- Discovering Company: GE Healthcare Systems Trade Development (Shanghai) Co., Ltd.
- Manufacturing Company: GE Medical Systems SCS
- Summary: The National Medical Products Administration (NMPA) published a notice on April 28, 2014, detailing a voluntary recall initiated by GE Medical Systems SCS for specific angiography imaging systems. GE Healthcare Systems Trade Development (Shanghai) Co., Ltd., the responsible unit in China, reported on April 18, 2014, that Innova systems, including models like INNOVA 3100 and 4100, equipped with CE-certified power distribution boxes, presented significant issues. The primary violation identified was the system's potential failure to start properly after power-on or a system reset. Crucially, these devices also risked unexpected shutdown during medical inspections, which could result in a complete loss of real-time interventional imaging. This recall was initiated under the NMPA's regulatory framework to address these critical performance defects. While the recall affects international markets such as Singapore and the European Economic Area, GE confirmed that the identified faulty product batches were not sold in China. Consequently, no direct corrective actions were required within the Chinese market. However, the NMPA mandated that provincial and municipal food and drug administrations enhance supervision and management of similar products to uphold public safety and regulatory compliance.

Company: https://www.globalkeysolutions.net/companies/ge-medical-systems-scs/7eda2422-02cb-413a-8d7d-411a779dd49c/